Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chromax Chromium Picolinate Patent Infringement Alleged By AMBI

This article was originally published in The Tan Sheet

Executive Summary

Nutrition 21 "will continue to seek legal remedies" against companies infringing on its Chromax chromium picolinate use patents, the AMBI subsidiary said May 9, while announcing the latest in a series of suits that began last August.

You may also be interested in...



AMBI

Rights to chromium use patents for relieving symptoms of depression, PMS obtained by Chromax marketer under licensing agreement with patent holder Malcolm McLeod, MD, University of North Carolina School of Medicine, firm announces. McLeod has conducted research on chromium use for depression and severe cases of PMS, AMBI notes; additional human studies are underway. AMBI holds numerous patents on chromium picolinate supplement use and has sued several companies for patent infringement (1"The Tan Sheet" May 22, 2000, p. 12)

AMBI

Rights to chromium use patents for relieving symptoms of depression, PMS obtained by Chromax marketer under licensing agreement with patent holder Malcolm McLeod, MD, University of North Carolina School of Medicine, firm announces. McLeod has conducted research on chromium use for depression and severe cases of PMS, AMBI notes; additional human studies are underway. AMBI holds numerous patents on chromium picolinate supplement use and has sued several companies for patent infringement (1"The Tan Sheet" May 22, 2000, p. 12)

AMBI

Rights to chromium use patents for relieving symptoms of depression, PMS obtained by Chromax marketer under licensing agreement with patent holder Malcolm McLeod, MD, University of North Carolina School of Medicine, firm announces. McLeod has conducted research on chromium use for depression and severe cases of PMS, AMBI notes; additional human studies are underway. AMBI holds numerous patents on chromium picolinate supplement use and has sued several companies for patent infringement (1"The Tan Sheet" May 22, 2000, p. 12)

Related Content

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel